表紙
市場調査レポート

世界のヒト用ワクチン市場:2016年〜2020年

Global Human Vaccine Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 350483
出版日 ページ情報 英文 111 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
世界のヒト用ワクチン市場:2016年〜2020年 Global Human Vaccine Market 2016-2020
出版日: 2016年01月20日 ページ情報: 英文 111 Pages
概要

アメリカ疾病管理予防センター (CDC) によると、ワクチンとはヒトの免疫システムを刺激し、特定の疾病に対する免疫を作り出すことにより、その疾病からヒトを防御するものです。世界のヒト用ワクチン市場は、2016年〜2020年の期間中、CAGRが11.69%成長すると見込まれております。

当レポートでは、世界のヒト用ワクチン市場について調査分析を行い、産業の概要、地域市場の概要、市場促進因子、市場の課題、市場動向、主要ベンダーなどについてまとめています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

第3章 市場調査の方法

  • 調査方法
  • 経済指標

第4章 イントロダクション

第5章 ワクチンの承認プロセス

第6章 パイプライン・ポートフォリオ

第7章 市場の状況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 市場セグメンテーション:人用ワクチンの種類

  • 弱毒化生ワクチン
  • 死菌ワクチン
  • トキソイドワクチン
  • 遺伝子組み換えワクチン
  • 合成ワクチン
  • 樹状細胞ワクチン
  • 共役ワクチン
  • サブユニット・ワクチン

第9章 市場セグメンテーション:組成

  • 非混合ワクチン
  • 混合ワクチン

第10章 市場セグメンテーション:投与経路

  • 経口投与
  • 筋肉内投与
  • 経鼻投与
  • 皮内投与

第11章 市場セグメンテーション:ヒト用ワクチンの種類

第12章 世界のヒト用治療ワクチン市場

第13章 世界のヒト用予防ワクチン市場

第14章 世界のヒト用小児予防ワクチン市場

第15章 世界のヒト用成人予防ワクチン市場7

第16章 地域別セグメンテーション

  • 南北アメリカ
  • 市場規模と予測
  • 欧州/中東/アフリカ
  • 市場規模と予測
  • アジア太平洋地域
  • 市場規模と予測

第17章 市場促進因子

  • ワクチンと予防接種への関心の高まり
  • 全国的な予防接種スケジュールの組み入れ
  • 小児用ワクチンの需要の高さ
  • 感染症の流行の増加

第18章 促進因子の影響

第19章 市場の課題

第20章 促進因子と課題の影響

第21章 市場動向

第22章 ベンダーの状況

  • 競合シナリオ

第23章 主要ベンダー分析

第24章 付録

第25章 Technavioのその他のレポート

別紙一覧

目次
Product Code: IRTNTR8142

About Human Vaccine

According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person's immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose.

Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases.

Technavio's analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • Europe

Technavio's report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Abbott
  • AstraZeneca
  • Bavarian Nordic
  • Baxter
  • Bharat Biotech
  • Bharat Immunologicals and Biologicals
  • bioCSL
  • Bio Med
  • Crucell
  • Dynavax Technologies
  • Indian Immunologicals
  • Janssen Pharmaceuticals
  • Kaketsuken
  • LG Life Sciences
  • Mitsubishi Tanabe Pharma
  • Lupin
  • Nuron
  • Novartis
  • Protein Sciences Corporation
  • Panacea Biotec
  • Roche
  • Serum Institute of India
  • Shenzhen Kangtai Biological Products
  • Sinovac Biotech
  • S K Chemicals
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals
  • Zydus Cadila

Market driver

  • Growing awareness about vaccination and immunization programs
  • For a full, detailed list, view our report

Market challenge

  • Inadequate vaccination coverage
  • For a full, detailed list, view our report

Market trend

  • Increase in strategic alliance and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Vaccine approval process

  • Vaccines price list

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of human vaccine

  • Live attenuated vaccine
  • Killed vaccine
  • Toxoid vaccine
  • Genetically modified/engineered vaccine
  • Synthetic vaccines
  • Dendritic cells vaccines
  • Conjugate vaccines
  • Subunit vaccines

PART 09: Market segmentation by composition

  • Mono vaccine
  • Combination vaccines

PART 10: Market segmentation by route of administration

  • Oral vaccines
  • Intramuscular vaccines
  • Intranasal vaccines
  • Intradermal vaccines

PART 11: Market segmentation by type of human vaccine

PART 12: Global therapeutic human vaccines market

  • Market overview
  • Market size and forecast

PART 13: Global preventable human vaccines market

  • Market overview
  • Market size and forecast

PART 14: Global pediatric preventable human vaccines market

  • Market size and forecast

PART 15: Global adult preventable human vaccines market

  • Market size and forecast

PART 16: Geographical segmentation

  • Human vaccines market in the Americas
  • Market size and forecast
  • Human vaccines market in EMEA
  • Market size and forecast
  • Human vaccines market in APAC
  • Market size and forecast

PART 17: Market drivers

  • Growing awareness about vaccination and immunization programs
  • Inclusion in national immunization schedule
  • High demand for pediatric vaccines
  • Increase in prevalence of infectious diseases

PART 18: Impact of drivers

PART 19: Market challenges

  • Inadequate vaccination coverage
  • Vaccine storage and handling issues
  • High risk associated with vaccine development
  • Stringent regulatory process
  • Misperception about vaccines
  • Adverse side effects of vaccines

PART 20: Impact of drivers and challenges

PART 21: Market trends

  • Increase in strategic alliance and M&A
  • Entry of novel vaccines
  • Increase in investment
  • Focus on emerging markets
  • Emergence of resistant strains
  • Public-private initiatives

PART 22: Vendor landscape

  • Competitive scenario

PART 23: Key vendor analysis

  • GSK
  • Sanofi
  • Merck
  • Pfizer
  • Other prominent vendors

PART 24: Appendix

  • List of abbreviations

PART 25: Explore Technavio

List of Exhibits

  • List of Exhibits
  • Exhibit 01: Product offerings
  • Exhibit 02: Requirements for BLA submission in the US
  • Exhibit 03: Developmental steps required to reach the vaccine licensing stage
  • Exhibit 04: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
  • Exhibit 05: Regulatory testing of licensed vaccines
  • Exhibit 06: Pediatric/VFC vaccine price list
  • Exhibit 07: Pediatric influenza vaccine price list
  • Exhibit 08: Adult vaccine price list
  • Exhibit 09: Adult influenza vaccine price list
  • Exhibit 10: GlaxoSmithKline: Vaccine pipeline
  • Exhibit 11: Novartis: Vaccine pipeline
  • Exhibit 12: Merck: vaccine pipeline
  • Exhibit 13: Pfizer: vaccine pipeline
  • Exhibit 14: Sanofi: vaccine pipeline
  • Exhibit 15: TuBerculosis Vaccine Initiative (TBVI): vaccine pipeline
  • Exhibit 16: Some pipeline compounds under development in 2015
  • Exhibit 17: Top 10 pharmaceutical companies based on global vaccine revenues in 2014 ($ millions)
  • Exhibit 18: Global human vaccines market 2015-2020 ($ billions)
  • Exhibit 19: SWOT analysis
  • Exhibit 20: Five forces analysis
  • Exhibit 21: Global human vaccines market segmentation by type of vaccine
  • Exhibit 22: Examples of vaccines by type
  • Exhibit 23: Global human vaccines market segmentation by composition
  • Exhibit 24: Global human vaccines market segmentation by route of administration
  • Exhibit 25: Route of administration for different vaccines
  • Exhibit 26: Global human vaccines market types
  • Exhibit 27: Global preventable and therapeutic human vaccines market share 2015
  • Exhibit 28: Global therapeutic human vaccines market 2015-2020 ($ billions)
  • Exhibit 29: Global preventable human vaccines market 2015-2020 ($ billions)
  • Exhibit 30: Global preventable human vaccines market categories
  • Exhibit 31: Global pediatric and adult preventable human vaccines market share 2015
  • Exhibit 32: Global pediatric preventable human vaccines market segmentation 2015
  • Exhibit 33: Global pediatric preventable human vaccines market 2015-2020 ($ billions)
  • Exhibit 34: Global adult preventable human vaccines market share 2015
  • Exhibit 35: Global adult preventable human vaccines market 2015-2020 ($ billions)
  • Exhibit 36: Global human vaccines market by geography 2015
  • Exhibit 37: Global human vaccines market by region 2015-2020 ($ billions)
  • Exhibit 38: Human vaccines market in the Americas 2015-2020 ($ billions)
  • Exhibit 39: Human vaccines market in EMEA 2015-2020 ($ billions)
  • Exhibit 40: Human vaccines market in APAC 2015-2020 ($ billions)
  • Exhibit 41: Impact of drivers
  • Exhibit 42: Global immunization coverage 2014
  • Exhibit 43: A typical cold chain process
  • Exhibit 44: Adverse effects associated with some preventable human vaccines
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: M&A in the vaccine industry
  • Exhibit 47: Overview of major vaccine-related acquisitions (2005-2012)
  • Exhibit 48: Market share analysis of top pharma vaccine companies, 2014
  • Exhibit 49: GSK: Business segmentation by revenue 2014
  • Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 51: GSK: Geographical segmentation by revenue 2014
  • Exhibit 52: GSK: YoY revenue growth of Infanrix/Pediarix 2012-2014 ($ millions)
  • Exhibit 53: GSK: YoY revenue growth of Hepatitis vaccine 2012-2014 ($ millions)
  • Exhibit 54: GSK: YoY revenue growth of Synflorix 2012-2014 ($ millions)
  • Exhibit 55: GSK: YoY revenue growth of Rotarix 2012-2014 ($ millions)
  • Exhibit 56: GSK: YoY revenue growth of Boostrix 2012-2014 ($ millions)
  • Exhibit 57: GSK: Meningitis vaccine revenue 2013 and 2014 ($ millions)
  • Exhibit 58: GSK: Travel and paediatrics vaccine revenue 2013 and 2014 ($ millions)
  • Exhibit 59: Key takeaways
  • Exhibit 60: Sanofi: Business segmentation by revenue 2014
  • Exhibit 61: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 62: Sanofi: Geographical segmentation by revenue 2014
  • Exhibit 63: Sanofi: YoY revenue growth of Polio/pertussis/Hib vaccines ($ millions)
  • Exhibit 64: Sanofi: YoY revenue growth of influenza vaccines 2012-2014 ($ millions)
  • Exhibit 65: Sanofi: YoY revenue growth of meningitis/pneumonia vaccine 2012-2014 ($ millions)
  • Exhibit 66: Sanofi: YoY revenue growth of adult booster vaccine 2012-2014 ($ millions)
  • Exhibit 67: Sanofi: YoY revenue growth of travel and other endemic vaccines 2012-2014 ($ millions)
  • Exhibit 68: Key takeaways
  • Exhibit 69: Merck: Business segmentation by revenue 2014
  • Exhibit 70: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 71: Merck: Geographical segmentation by revenue 2014
  • Exhibit 72: Merck: YoY revenue growth of Gardasil 2012-2014 ($ millions)
  • Exhibit 73: Merck: YoY revenue growth of ProQuad/MMR II/Varivax 2012-2014 ($ millions)
  • Exhibit 74: Merck: YoY revenue growth of Zostavax 2012-2014 ($ millions)
  • Exhibit 75: Merck: YoY revenue growth of Pneumovax 23 2012-2014 ($ millions)
  • Exhibit 76: Merck: YoY revenue growth of RotaTeq 2012-2014 ($ millions)
  • Exhibit 77: Key takeaways
  • Exhibit 78: Pfizer: Business segmentation by revenue 2014 0
  • Exhibit 79: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions) 1
  • Exhibit 80: Pfizer: Geographical segmentation by revenue 2014 2
  • Exhibit 81: Pfizer: YoY revenue growth of Prevnar family 2012-2014 ($ millions) 3
  • Exhibit 82: Key takeaways
Back to Top